文献速递血脂与心血管预防冠心病

冠状动脉钙化在基于AHA PREVENT计算的他汀类药物适用性评估中的作用:MESA研究启示

The Role of Coronary Artery Calcium in Statin Eligibility Based on the American Heart Association's PREVENT Calculator: Insights From MESA.
PubMed 文献 · J Am Coll Cardiol · 2026-07-15

该研究基于MESA队列5698名参与者,评估在他汀适用性分组和PREVENT-ASCVD风险类别内不同CAC分层的ASCVD事件率。结果显示CAC在他汀决策不确定时临床价值最大,尤其 borderline 风险人群;已符合治疗阈值者即使CAC为0事件率仍升高,提示不应据此停用他汀。

要点

  • CAC在他汀决策不确定时价值最大,尤其 borderline 风险人群。
  • 已符合治疗阈值者即使CAC为0,事件率仍升高,不应据此停用他汀。
  • PREVENT时代CAC用于细化阈值附近风险、提供绝对风险背景和指导预防强度。

核心结论

  • CAC在他汀治疗决策不确定时临床价值最大,尤其 borderline 预测风险个体。
  • 已符合指南治疗阈值者即使CAC为0,观察到的ASCVD事件率仍升高,提示不应普遍用CAC 0停用他汀。
  • 研究支持PREVENT时代以指南为中心使用CAC:细化阈值附近风险、提供绝对风险背景、指导预防强度。

研究设计与样本

  • 研究纳入MESA多民族队列个体。
  • 按他汀适用性分为推荐、考虑、不推荐三组。
  • 将LDL-C 70-189 mg/dL且无糖尿病者按10年PREVENT-ASCVD风险分组:<3%、3%至<5%、5%至<10%、≥10%。
  • 计算各他汀适用性组和PREVENT-ASCVD风险类别内不同CAC分层的每1000人年发病率。

主要发现

  • 共纳入5698名参与者,平均年龄61.5±10.3岁,52.8%为女性。
  • 他汀不推荐1924人(33.8%),考虑897人(15.7%),推荐2877人(50.5%)。
  • 无CAC者中,不推荐、考虑、推荐他汀组的每1000人年事件率分别为1.2、2.7、5.8。
  • CAC>0者中,不推荐、考虑、推荐他汀组的每1000人年事件率分别为4.5、5.2、16.6。
  • CAC 0 vs CAC>0的每1000人年事件率:10年PREVENT-ASCVD风险<3%为1.1和3.0,3%至<5%为2.7和5.2,5%至<10%为5.9和11.3,≥10%为6.2和20.9。

临床怎么用

  • 在他汀治疗决策不确定时,尤其 borderline 预测风险个体,可考虑用CAC细化风险评估。
  • 已符合指南他汀治疗阈值者,即使CAC为0也不应普遍停用他汀。
  • CAC可用于在PREVENT时代细化治疗阈值附近风险、提供绝对风险背景并指导预防强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2026 American College of Cardiology/American Heart Association/multisociety dyslipidemia guideline incorporates the PREVENT atherosclerotic cardiovascular disease (ASCVD) equations for estimation of 10-year ASCVD risk, replacing the Pooled Cohort Equations used in previous prevention guidelines. Coronary artery calcium (CAC) has historically been used to refine risk assessment when treatment decisions are uncertain. OBJECTIVES: In this study, the authors sought to evaluate cardiovascular event rates across CAC strata within statin eligibility groups and 10-year PREVENT risk categories. METHODS: Individuals from the MESA (Multi-Ethnic Study of Atherosclerosis) were included. Three groups were created based on statin eligibility: statin recommended, considered, and not recommended. In addition, participants with a low-density lipoprotein cholesterol 70 to 189 mg/dL without diabetes were grouped by 10-year PREVENT-ASCVD risk categories: <3% (low risk), 3% to <5% (borderline risk), 5% to <10% (intermediate risk), and ≥10% (high risk). Incidence rates per 1,000 person-years were calculated across CAC strata within statin eligibility groups and PREVENT-ASCVD risk categories. RESULTS: Among the 5,698 participants included in this analysis, the mean age was 61.5 ± 10.3 years and 52.8% were female. Statin therapy was not recommended in 1,924 participants (33.8%), considered in 897 participants (15.7%), and recommended in 2,877 participants (50.5%). The event rates per 1,000 person-years in those without CAC in the not recommended, considered, and recommended statin groups were 1.2, 2.7, and 5.8, respectively. In those with CAC >0, the event rates were 4.5, 5.2, and 16.6, respectively. The event rates per 1,000 person-years in participants with CAC 0 vs CAC >0 were, respectively, 1.1 and 3.0 for 10-year PREVENT-ASCVD risk <3%, 2.7 and 5.2 for 10-year PREVENT-ASCVD risk 3% to <5%, 5.9 and 11.3 for 10-year PREVENT-ASCVD risk 5% to <10%, and 6.2 and 20.9 for 10-year PREVENT-ASCVD risk ≥10%. CONCLUSIONS: In this large multiethnic cohort, CAC provided its greatest clinical value when statin treatment decisions were uncertain, particularly among individuals with borderline predicted risk. Among participants who already met guideline-based treatment thresholds, observed ASCVD event rates remained elevated even when CAC was absent, suggesting that CAC 0 should not generally be used to withhold statin therapy in these individuals. These findings support a guideline-centered role for CAC in the PREVENT era: refining risk near treatment thresholds, contextualizing absolute risk, and informing the intensity of preventive efforts.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Rikhi R, Chen H, Mirzai S, et al. The Role of Coronary Artery Calcium in Statin Eligibility Based on the American Heart Association's PREVENT Calculator: Insights From MESA. J Am Coll Cardiol. 2026. PMID: 42455102. doi:10.1016/j.jacc.2026.05.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。